Investigational Alzheimer’s treatment Aducanumab accepted into EMA’s PRIME programme
2 June 2016 | By Victoria White, Digital Content Producer
PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines...